Imunon Inc Financials

IMNN

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

Financial Health Signals

Piotroski F-Score Weak

1/9

Imunon Inc passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

1.01x

For every $1 of reported earnings, Imunon Inc generates $1.01 in operating cash flow (-$18.9M OCF vs -$18.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

This page shows Imunon Inc (IMNN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Export CSV

Key Financial Metrics

Revenue

N/A

EBITDA

-$18.9M

YoY+9.1%

Imunon Inc's EBITDA was -$18.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 9.1% from the prior year.

Free Cash Flow

-$18.9M

YoY+3.0%

Imunon Inc generated -$18.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 3.0% from the prior year.

Net Income

-$18.6M

YoY+4.6%

Imunon Inc reported -$18.6M in net income in fiscal year 2024. This represents an increase of 4.6% from the prior year.

EPS (Diluted)

$-1.62

Imunon Inc earned $-1.62 per diluted share (EPS) in fiscal year 2024. This represents an increase of 25.0% from the prior year.

Cash & Debt

$5.9M

YoY+0.6%

5Y CAGR-3.1%

10Y CAGR-7.4%

Imunon Inc held $5.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

966,712

Imunon Inc had 966,712 shares outstanding in fiscal year 2024. This represents a decrease of 89.7% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$11.6M

YoY+3.1%

5Y CAGR-2.3%

10Y CAGR-2.5%

Imunon Inc invested $11.6M in research and development in fiscal year 2024. This represents an increase of 3.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$30K

YoY-93.5%

5Y CAGR-39.0%

10Y CAGR-26.8%

Imunon Inc invested $30K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 93.5% from the prior year.

IMNN Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	$500K0.0%	$500K0.0%	$500K0.0%	$500K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.6M+3.1%	$11.3M-3.8%	$11.7M+10.5%	$10.6M-6.4%	$11.3M-13.2%	$13.1M
SG&A Expenses	$7.5M-23.1%	$9.7M-28.8%	$13.7M+25.7%	$10.9M+42.5%	$7.6M-4.5%	$8.0M
Operating Income	-$19.1M+9.0%	-$21.0M+15.6%	-$24.9M-18.6%	-$21.0M-13.6%	-$18.5M+10.1%	-$20.6M
Interest Expense	N/A	$197K-96.1%	$5.0M+782.4%	$570K-55.9%	$1.3M-7.3%	$1.4M
Income Tax	N/A	-$1.3M+18.3%	-$1.6M-13.3%	-$1.4M+25.0%	-$1.8M-1.6%	-$1.8M
Net Income	-$18.6M+4.6%	-$19.5M+45.6%	-$35.9M-72.8%	-$20.8M+3.3%	-$21.5M-27.5%	-$16.9M
EPS (Diluted)	$-1.62	$-2.16+57.1%	$-5.03	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$1.9M+54.8%	$1.2M-43.3%	$2.2M-34.3%	$3.3M+16.8%	$2.8M-14.4%	$3.3M	N/A	$2.0M
SG&A Expenses	$1.6M+2.3%	$1.5M-22.2%	$2.0M+18.7%	$1.7M-24.0%	$2.2M+27.7%	$1.7M	N/A	$1.9M
Operating Income	-$3.5M-25.6%	-$2.8M+33.2%	-$4.1M+16.5%	-$5.0M+1.0%	-$5.0M0.0%	-$5.0M	N/A	-$3.9M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.4M-25.1%	-$2.7M+33.2%	-$4.1M+15.3%	-$4.8M-1.2%	-$4.8M+2.9%	-$4.9M	N/A	-$3.5M
EPS (Diluted)	$-1.16+46.0%	$-2.15	$-0.28	$-3.76	$-7.64-1369.2%	$-0.52	N/A	$-0.37

IMNN Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$9.7M-55.7%	$21.9M-50.2%	$44.0M-40.6%	$74.0M+97.3%	$37.5M-2.0%	$38.3M
Current Assets	$8.0M-56.1%	$18.2M-50.4%	$36.8M-29.2%	$51.9M+175.9%	$18.8M+16.0%	$16.2M
Cash & Equivalents	$5.9M+0.6%	$5.8M-49.2%	$11.5M-41.3%	$19.6M+14.1%	$17.2M+149.7%	$6.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0	$0	N/A	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	$2.0M0.0%	$2.0M
Total Liabilities	$5.5M-35.8%	$8.5M-41.8%	$14.6M-19.7%	$18.3M-3.5%	$18.9M-20.2%	$23.7M
Current Liabilities	$4.8M-35.2%	$7.4M-26.4%	$10.0M+48.3%	$6.8M+0.2%	$6.8M-14.5%	$7.9M
Long-Term Debt	N/A	N/A	$6.0M	N/A	$5.1M-48.5%	$9.8M
Total Equity	$4.2M-68.3%	$13.4M-54.4%	$29.3M-47.4%	$55.8M+199.8%	$18.6M+27.8%	$14.6M
Retained Earnings	-$406.8M-4.8%	-$388.2M-5.3%	-$368.7M-10.8%	-$332.8M-6.7%	-$312.0M-7.4%	-$290.5M

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$9.0M+2.3%	$8.8M+28.1%	$6.9M-29.4%	$9.7M+0.3%	$9.7M-32.3%	$14.3M-34.6%	$21.9M-11.1%	$24.7M
Current Assets	$7.3M+5.3%	$6.9M+35.3%	$5.1M-36.4%	$8.0M+4.7%	$7.6M-36.8%	$12.1M-33.7%	$18.2M-16.0%	$21.7M
Cash & Equivalents	$5.3M+11.0%	$4.7M+64.7%	$2.9M-51.1%	$5.9M+10.7%	$5.3M+126.1%	$2.3M-59.8%	$5.8M-54.7%	$12.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	$0	N/A	N/A	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.9M-19.9%	$6.1M-4.4%	$6.4M+17.1%	$5.5M-8.0%	$6.0M+2.1%	$5.8M-31.7%	$8.5M+29.6%	$6.6M
Current Liabilities	$4.2M-21.1%	$5.3M-8.3%	$5.8M+21.1%	$4.8M-5.7%	$5.1M+5.4%	$4.8M-34.8%	$7.4M+39.0%	$5.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.1M+53.5%	$2.7M+488.4%	$452K-89.3%	$4.2M+13.4%	$3.7M-56.0%	$8.5M-36.5%	$13.4M-25.9%	$18.1M
Retained Earnings	-$417.1M-0.8%	-$413.6M-0.7%	-$410.9M-1.0%	-$406.8M-2.2%	-$397.9M-1.2%	-$393.1M-1.3%	-$388.2M-1.3%	-$383.3M

IMNN Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$18.9M+0.9%	-$19.0M+17.6%	-$23.1M-42.4%	-$16.2M-3.9%	-$15.6M+22.9%	-$20.3M
Capital Expenditures	$30K-93.5%	$452K+68.7%	$268K-14.1%	$312K+1532.2%	$19K-94.5%	$349K
Free Cash Flow	-$18.9M+3.0%	-$19.5M+16.7%	-$23.4M-41.3%	-$16.5M-5.7%	-$15.6M+24.1%	-$20.6M
Investing Cash Flow	$9.8M-10.7%	$11.0M+32.9%	$8.3M+127.5%	-$30.1M-480.1%	$7.9M+33.5%	$5.9M
Financing Cash Flow	$9.1M+349.0%	-$3.6M-154.1%	$6.7M-87.7%	$54.8M+204.5%	$18.0M+129.2%	$7.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$4.4M-50.5%	-$3.0M-3.7%	-$2.8M+35.6%	-$4.4M+1.9%	-$4.5M+23.3%	-$5.9M-55.7%	-$3.8M+15.7%	-$4.5M
Capital Expenditures	$0-100.0%	$17K-93.3%	$260K+1641.8%	$15K	$0-100.0%	$12K	$0-100.0%	$240K
Free Cash Flow	-$4.4M-49.6%	-$3.0M+4.4%	-$3.1M+30.0%	-$4.4M+1.5%	-$4.5M+23.5%	-$5.9M-56.0%	-$3.8M+20.0%	-$4.7M
Investing Cash Flow	$0+100.0%	-$17K+93.3%	-$260K-1641.8%	-$15K-100.2%	$7.5M+213.3%	$2.4M+172.1%	-$3.3M-131.0%	$10.7M
Financing Cash Flow	$5.0M+2.8%	$4.8M+4465.9%	$106K+3325.3%	-$3K	N/A	N/A	$30K-61.4%	$78K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMNN Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	-4984.3%-782.9pp	-4201.4%-504.2pp	-3697.3%+415.8pp	-4113.1%
Net Margin	N/A	N/A	-7179.6%-3025.8pp	-4153.9%+142.9pp	-4296.7%-926.4pp	-3370.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-191.6%-102.6pp	-89.0%-7.4pp	-81.6%-53.6pp	-28.1%+29.2pp	-57.3%-13.2pp	-44.0%
Current Ratio	1.67-0.8	2.47-1.2	3.66-4.0	7.67+4.9	2.79+0.7	2.06
Debt-to-Equity	1.29+0.7	0.64+0.4	0.20-0.1	0.33+0.1	0.27-0.4	0.67
FCF Margin	N/A	N/A	-4672.9%-1365.9pp	-3307.0%-179.5pp	-3127.6%+994.1pp	-4121.6%

Metric	Q3'25	Q2'25	Q1'25	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-38.1%-7.0pp	-31.2%+28.6pp	-59.8%-26.1pp	-33.7%+15.7pp	-49.4%-15.0pp	-34.4%	N/A	-14.1%
Current Ratio	1.73+0.4	1.30+0.4	0.88-0.8	1.67+0.2	1.51-1.0	2.51+0.0	2.47-1.6	4.09
Debt-to-Equity	1.20-1.1	2.30-11.9	14.18+12.9	1.29-0.3	1.59+0.9	0.69+0.0	0.64+0.3	0.36
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Briacell Therapeutics Corp BCTX

$25.3M

Nextcure NXTC

$45.9M

Biovie Inc BIVI

$9.6M

Carisma Therapeutics Inc CARM

$6.4M

Portage Biotech Inc PRTG

$15.5M

Frequently Asked Questions

Is Imunon Inc profitable?

No, Imunon Inc (IMNN) reported a net income of -$18.6M in fiscal year 2024.

What is Imunon Inc's earnings per share (EPS)?

Imunon Inc (IMNN) reported diluted earnings per share of $-1.62 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Imunon Inc's EBITDA?

Imunon Inc (IMNN) had EBITDA of -$18.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Imunon Inc's free cash flow?

Imunon Inc (IMNN) generated -$18.9M in free cash flow during fiscal year 2024. This represents a 3.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Imunon Inc's operating cash flow?

Imunon Inc (IMNN) generated -$18.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Imunon Inc's total assets?

Imunon Inc (IMNN) had $9.7M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Imunon Inc's capital expenditures?

Imunon Inc (IMNN) invested $30K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Imunon Inc spend on research and development?

Imunon Inc (IMNN) invested $11.6M in research and development during fiscal year 2024.

How many shares does Imunon Inc have outstanding?

Imunon Inc (IMNN) had 966,712 shares outstanding as of fiscal year 2024.

What is Imunon Inc's current ratio?

Imunon Inc (IMNN) had a current ratio of 1.67 as of fiscal year 2024, which is generally considered healthy.

What is Imunon Inc's debt-to-equity ratio?

Imunon Inc (IMNN) had a debt-to-equity ratio of 1.29 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Imunon Inc's return on assets (ROA)?

Imunon Inc (IMNN) had a return on assets of -191.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Imunon Inc's cash runway?

Based on fiscal year 2024 data, Imunon Inc (IMNN) had $5.9M in cash against an annual operating cash burn of $18.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Imunon Inc's Piotroski F-Score?

Imunon Inc (IMNN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Imunon Inc's earnings high quality?

Imunon Inc (IMNN) has an earnings quality ratio of 1.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.